Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience Wi...( - Clinical Trial Data and Emerging ...),Health

- Clinical Trial Data and Emerging Clinical Practice Experience Support

HYLENEX Efficacy and Safety -

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced the Original Article publication of the INFUSE-LR clinical trial results in the Journal of Palliative Medicine, the official journal of the American Academy of Palliative Medicine (Thomas JR et al. J Pall Med. December 2007; 19(6): 1312-1320). The authors of this publication concluded from this volunteer subject study that clinically relevant fluid volumes can be rapidly delivered subcutaneously (Sub-Q) with HYLENEX in a well-tolerated manner without the need for an infusion pump. The findings suggest that this method of hydration could potentially replace intravenous infusions in many clinical settings and that further studies with HYLENEX, in patients, are warranted.

This call for additional study of HYLENEX in the clinical setting with patients has been addressed in an earlier publication in this same journal (Pirrello R et al. Initial Experiences with Subcutaneous Recombinant Human Hyaluronidase (rHuPH20). J Pall Med. 2007;10(4):861-864). In this first publication of actual clinical experience with a series of patients administered the HYLENEX marketed drug product, 32 patients were treated with HYLENEX in a hospice setting over a six-month period. Of these, 26 received HYLENEX to enhance Sub-Q infusion with standard hydration fluids (normal saline, 5% dextrose in saline, and 5% dextrose) for symptom control of delirium, myoclonus, and mild-to-moderate dehydration. Flow rates up to 500 mL/hour w
'/>"/>